GILEAD SCIENCES, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
GILEAD SCIENCES, INC. (GILD) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $2.38 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-24
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.38B.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.39B.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.38B.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.39B.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $2.38B 10-K · filed 2026-02-24 |
| 2024-12-31 | $2.39B 10-K · filed 2025-02-28 |
| 2023-12-31 | $2.38B 10-K · filed 2024-02-23 |
| 2023-09-30 | $2.39B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.39B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $2.39B 10-Q · filed 2023-05-03 |
| 2022-12-31 | $1.78B 10-K · filed 2023-02-22 |
| 2022-09-30 | $1.78B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $1.78B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.78B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $1.78B 10-K · filed 2022-02-23 |
| 2021-09-30 | $1.76B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.76B 10-Q · filed 2021-08-05 |
| 2020-12-31 | $1.53B 10-K · filed 2021-02-25 |
| 2019-12-31 | $1.13B 10-K · filed 2020-02-25 |
| 2018-12-31 | $1.15B 10-K · filed 2019-02-26 |
| 2017-12-31 | $1.20B 10-K · filed 2018-02-27 |
| 2016-12-31 | $839.00M 10-K · filed 2017-02-27 |
| 2016-09-30 | $844.00M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $844.00M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $844.00M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $839.00M 10-K · filed 2016-02-24 |
| 2015-09-30 | $832.00M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $832.00M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $832.00M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $826.00M 10-K · filed 2015-02-25 |
| 2014-09-30 | $817.06M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $803.50M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $803.50M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $798.04M 10-K · filed 2014-02-25 |
| 2013-09-30 | $92.44M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $92.44M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $92.44M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $86.18M 10-K · filed 2013-02-27 |
| 2012-09-30 | $64.28M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $64.28M 10-Q · filed 2012-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |